
    
      41 patients will be enrolled in this trial with low grade lymphomas and will be given
      Ofatumumab 1000 mg and Bortezomib IV 1.6 mg/m2 weekly times 4 treatments and will then
      receive maintenance treatment with the 2 agents every 2 months for 1 year unless disease
      progression.
    
  